ReviewFrontiers in cardiovascular medicine2022
Right heart failure after left ventricular assist device: From mechanisms to treatments.
Review in Frontiers in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Minimally Invasive Left Ventricular Assist Device Implantation: A Systematic Review of Current Evidence on Clinical Outcomes and Surgical Approaches.Medical sciences (Basel, Switzerland) · 2025Pooled it
- A monolithic patient-specific 3D-0D model for In silico investigation of hemodynamics in patients with left ventricular assist devices.Biomechanics and modeling in mechanobiology · 2026Article
- Left ventricular assist devices and right heart dysfunction: a review of impact mechanisms, evaluation methods, and prevention and management.Journal of cardiothoracic surgery · 2026Review
- Preoperative Left Ventricular Thrombus and Midterm Outcomes Following Left Ventricular Assist Device Support.Journal of clinical medicine · 2026Article
- Assessment of Right Ventricular Adaptability to Pressure Overloading for Critical Therapeutic Decision-Making Processes.Journal of clinical medicine · 2026Review
- Active and passive cardiac indexes as complementary predictors of outcomes after left ventricular assist device implantation.The Journal of thoracic and cardiovascular surgery · 2026Article
- Sex-specific echocardiographic remodeling and prognostic value of left ventricular sphericity, pressure-dimension index, and myocardial work after durable LVAD implantation.Frontiers in cardiovascular medicine · 2026Article
- Advances in Mechanical Circulatory Support (MCS): Literature Review.Biomedicines · 2025Review
- Prediction of Right Heart Failure in LVAD Candidates: Current Approaches and Future Directions.Journal of cardiovascular development and disease · 2025Review
- Clinical Value of Bioactive Adrenomedullin and Proenkephalin A in Patients with Left Ventricular Assist Devices: An Observational Study.Journal of clinical medicine · 2025Article
- Not All Heart Failure Improves With Diuresis: A Lesson in Left Ventricular Assist Device Physiology.CASE (Philadelphia, Pa.) · 2025Article
- Contemporary treatment of right ventricular failure.JHLT open · 2025Review
- Patient-specific hemodynamic modeling to optimize LVAD speed and right heart health.JHLT open · 2025Article
- Comparative analysis of cardiac function before LVAD implantation in patients with and without early, acute right heart failure: insights from cardiac magnetic resonance.Frontiers in cardiovascular medicine · 2025Article
- Right heart failure after left ventricular assist device implantation: latest insights and knowledge gaps on mechanism and prediction.Frontiers in cardiovascular medicine · 2025Review
- Successful management of HeartMate 3 in a patient with arrhythmogenic right ventricular cardiomyopathy.Journal of artificial organs : the official journal of the Japanese Society for Artificial Organs · 2024Article
- The Prognostic Role of Pulmonary Arterial Elastance in Patients Undergoing Left Ventricular Assist Device Implantation: A Pilot Study.Journal of clinical medicine · 2024Article
- Model-Based Dose Identification of Dalbavancin for Long-Term Suppressive Outpatient Treatment of Ventricular Assist Device Infections.Antibiotics (Basel, Switzerland) · 2024Article
- Serum Uric Acid as an Indicator of Right Ventricular Dysfunction in LVAD Patients: A Preliminary Study.Biomedicines · 2024Article
- Association between pulmonary artery pulsatility and mortality after implantation of left ventricular assist device.ESC heart failure · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
Left ventricular assist device (LVAD) therapy is a lifesaving option for patients with medical therapy-refractory advanced heart failure. Depending on the definition, 5-44% of people supported with an LVAD develop right heart failure (RHF), which is associated with worse outcomes. The mechanisms related to RHF include patient, surgical, and hemodynamic factors. Despite significant progress in understanding the roles of these factors and improvements in surgical techniques and LVAD technology, this complication is still a substantial cause of morbidity and mortality among LVAD patients. Additionally, specific medical therapies for this complication still are lacking, leaving cardiac transplantation or supportive management as the only options for LVAD patients who develop RHF. While significant effort has been made to create algorithms aimed at stratifying risk for RHF in patients undergoing LVAD implantation, the predictive value of these algorithms has been limited, especially when attempts at external validation have been undertaken. Perhaps one of the reasons for poor performance in external validation is related to differing definitions of RHF in external cohorts. Additionally, most research in this field has focused on RHF occurring in the early phase (i.e., ≤1 month) post LVAD implantation. However, there is emerging recognition of late-onset RHF (i.e., > 1 month post-surgery) as a significant cause of morbidity and mortality. Late-onset RHF, which likely has a unique physiology and pathogenic mechanisms, remains poorly characterized. In this review of the literature, we will describe the unique right ventricular physiology and changes elicited by LVADs that might cause both early- and late-onset RHF. Finally, we will analyze the currently available treatments for RHF, including mechanical circulatory support options and medical therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.